HGSI completes Phase IIa Repifermin enrollment

Human Genome Sciences (HGSI) completed patient enrollment in a double-blind, dose-escalation Phase IIa trial of its repifermin to treat cancer therapy-induced mucositis. Data from the trial are to be ...